SOUTH SAN FRANCISCO, Calif.--Axys Pharmaceuticals announced that is has successfully completed the transfer of its proprietary bioinformatics platform to and attained two separate milestones in its psychiatric genomics collaboration with the Parke-Davis Pharmaceutical Research division of Warner Lambert. Tim Harris, Axys's senior vice-president of research, said the company has transferred to Parke-Davis a set of robust software tools that integrate genetic, genomic, and biological data to help researchers integrate and maintain key public and proprietary information on genes of interest.
The companies initiated a gene identification and function research collaboration in the area of schizophrenia and bi polar disorder in November 1997. Wendell Wierenga, Parke-Davis's senior vice-president, said the milestone "represents a significant advance toward understanding the causes of these psychiatric disorders." He added, "The bioinformatics software will serve as a key component in our overall drug discovery efforts."